Pharsight

Xarelto patents expiration

XARELTO's oppositions filed in EPO

XARELTO Litigations

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7585860 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(3 years ago)

US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7585860 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(3 years ago)

US7592339 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(3 years ago)

US9415053 JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
Nov, 2024

(5 months from now)

US7157456

(Pediatric)

JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Feb, 2025

(8 months from now)

US9415053

(Pediatric)

JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
May, 2025

(11 months from now)

US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Feb, 2034

(9 years from now)

US9539218

(Pediatric)

JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Aug, 2034

(10 years from now)

US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events
Jan, 2039

(14 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events
Jul, 2039

(15 years from now)

Xarelto is owned by Janssen Pharms.

Xarelto contains Rivaroxaban.

Xarelto has a total of 11 drug patents out of which 3 drug patents have expired.

Expired drug patents of Xarelto are:

  • US7585860
  • US7592339
  • US7585860

Xarelto was authorised for market use on 11 October, 2018.

Xarelto is available in for suspension;oral, tablet;oral dosage forms.

Xarelto can be used as treatment of deep vein thrombosis (dvt), reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily, prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days, reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism, prophylaxis of deep vein thrombosis (dvt).

Drug patent challenges can be filed against Xarelto from 24 February, 2024.

The generics of Xarelto are possible to be released after 31 July, 2039.

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-867) Aug 23, 2024
Pediatric Exclusivity(PED) Feb 23, 2025
New Indication(I-824) Oct 11, 2021
New Dosing Schedule(D-168) Oct 27, 2020
New Indication(I-810) Oct 11, 2022
M(M-284) Mar 10, 2023
New Indication(I-660) Nov 02, 2015
New Indication(I-661) Nov 02, 2015
New Indication(I-662) Nov 02, 2015
New Chemical Entity Exclusivity(NCE) Jul 01, 2016
New Indication(I-643) Nov 04, 2014

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using RIVAROXABAN ingredient

NCE-1 date:

24 February, 2024

Market Authorisation Date:

11 October, 2018

Treatment:

Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Treatment of deep vein thrombosis (dvt); Prophylaxis of pe, dvt and...

Dosage:

TABLET;ORAL; FOR SUSPENSION;ORAL

How can I launch a generic of XARELTO before its drug patent expiration?

More Information on Dosage

XARELTO family patents

Family Patents